Some Big accounts like Rajat Pharma estimated dues :290 Cr), as per news, has contributed to Q2 lower EPS.These dues are not yet LOST, but is under NPA provision.
I expect higher EPS and lower NPA in remaining Qs.The overall EPS may at least be equal to last year EPS of around 47.
At a P/E multiple of at least 10, the fair price for BOI can be around 470.But then, we all want to see the next Q EPS.Till then , BOI is likely to be available at sub 400 levels.
| NIFTY 
